A meta-analysis of randomized controlled trials evaluated the effectiveness and side effects of opioids for chronic noncancer pain (CNCP). The study included 41 trials involving 6019 patients, with 80% having nociceptive pain (e.g., osteoarthritis, rheumatoid arthritis, back pain), 12% neuropathic pain (e.g., postherpetic neuralgia, diabetic neuropathy), 7% fibromyalgia, and 1% mixed pain. Most studies had high methodological quality. Opioids, classified as weak (tramadol, codeine, propoxyphene) or strong (morphine, oxycodone), were more effective than placebo for pain and functional outcomes in patients with nociceptive or neuropathic pain or fibromyalgia. Strong opioids were significantly more effective than naproxen and nortriptyline for pain relief but not for functional outcomes. The most common side effects were constipation and nausea, which were clinically and statistically significant. The study found that opioids were more effective than other drugs for pain relief in certain cases, but other drugs performed better for functional outcomes. Only strong opioids were significantly more effective than other drugs for pain relief. Side effects of opioids were generally mild, with constipation and nausea being the most common. The study also noted that opioids may lead to sexual dysfunction and addiction, though these were not well studied in the trials. The majority of the studies were funded by the pharmaceutical industry, raising concerns about potential bias. The review concluded that opioids are effective for CNCP, but their long-term use may lead to tolerance, addiction, and other complications. The studies included in the meta-analysis were relatively short, and more than one-third of participants dropped out of the trials. The results were consistent with other recent reviews, which found that opioids can provide significant pain relief for CNCP but may have limited long-term benefits. The study emphasized the need for well-designed equivalence trials to compare opioids with other nonopioid drugs and to assess long-term complications such as addiction and sexual dysfunction. Future research should focus on long-term outcomes and methodological rigor to better understand the risks and benefits of opioid use for chronic noncancer pain.A meta-analysis of randomized controlled trials evaluated the effectiveness and side effects of opioids for chronic noncancer pain (CNCP). The study included 41 trials involving 6019 patients, with 80% having nociceptive pain (e.g., osteoarthritis, rheumatoid arthritis, back pain), 12% neuropathic pain (e.g., postherpetic neuralgia, diabetic neuropathy), 7% fibromyalgia, and 1% mixed pain. Most studies had high methodological quality. Opioids, classified as weak (tramadol, codeine, propoxyphene) or strong (morphine, oxycodone), were more effective than placebo for pain and functional outcomes in patients with nociceptive or neuropathic pain or fibromyalgia. Strong opioids were significantly more effective than naproxen and nortriptyline for pain relief but not for functional outcomes. The most common side effects were constipation and nausea, which were clinically and statistically significant. The study found that opioids were more effective than other drugs for pain relief in certain cases, but other drugs performed better for functional outcomes. Only strong opioids were significantly more effective than other drugs for pain relief. Side effects of opioids were generally mild, with constipation and nausea being the most common. The study also noted that opioids may lead to sexual dysfunction and addiction, though these were not well studied in the trials. The majority of the studies were funded by the pharmaceutical industry, raising concerns about potential bias. The review concluded that opioids are effective for CNCP, but their long-term use may lead to tolerance, addiction, and other complications. The studies included in the meta-analysis were relatively short, and more than one-third of participants dropped out of the trials. The results were consistent with other recent reviews, which found that opioids can provide significant pain relief for CNCP but may have limited long-term benefits. The study emphasized the need for well-designed equivalence trials to compare opioids with other nonopioid drugs and to assess long-term complications such as addiction and sexual dysfunction. Future research should focus on long-term outcomes and methodological rigor to better understand the risks and benefits of opioid use for chronic noncancer pain.